Changyu Pan

12.0k total citations
95 papers, 2.4k citations indexed

About

Changyu Pan is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Changyu Pan has authored 95 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Endocrinology, Diabetes and Metabolism, 34 papers in Molecular Biology and 17 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Changyu Pan's work include Diabetes Treatment and Management (36 papers), Diabetes Management and Research (29 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers). Changyu Pan is often cited by papers focused on Diabetes Treatment and Management (36 papers), Diabetes Management and Research (29 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (26 papers). Changyu Pan collaborates with scholars based in China, United States and United Kingdom. Changyu Pan's co-authors include Yiming Mu, Wenying Yang, Jianping Weng, Juming Lu, Dayi Hu, Linong Ji, Juming Lu, Baoan Wang, Norella Kong and Ming Wai Yeung and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Changyu Pan

91 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changyu Pan China 27 1.7k 565 334 312 299 95 2.4k
Nanwei Tong China 25 1.1k 0.6× 779 1.4× 407 1.2× 234 0.8× 300 1.0× 124 2.4k
Naohiko Furuyoshi Japan 7 1.8k 1.1× 480 0.8× 339 1.0× 244 0.8× 151 0.5× 11 2.5k
Mary Lou Perry United States 14 1.7k 1.0× 451 0.8× 577 1.7× 224 0.7× 296 1.0× 26 2.6k
S. Motoyoshi Japan 7 1.8k 1.1× 497 0.9× 397 1.2× 260 0.8× 153 0.5× 12 2.5k
Sam Dagogo‐Jack United States 15 1.2k 0.7× 537 1.0× 411 1.2× 237 0.8× 243 0.8× 40 1.8k
Giuseppe Seghieri Italy 32 1.3k 0.8× 560 1.0× 618 1.9× 490 1.6× 276 0.9× 115 3.3k
Tae Jung Oh South Korea 26 1.4k 0.8× 720 1.3× 615 1.8× 272 0.9× 335 1.1× 122 2.5k
György Jermendy Hungary 26 1.1k 0.7× 471 0.8× 391 1.2× 530 1.7× 229 0.8× 151 2.1k
Adriaan Kooy Netherlands 20 1.3k 0.8× 833 1.5× 502 1.5× 245 0.8× 253 0.8× 46 2.4k
Chul Sik Kim South Korea 25 661 0.4× 476 0.8× 289 0.9× 230 0.7× 256 0.9× 97 1.6k

Countries citing papers authored by Changyu Pan

Since Specialization
Citations

This map shows the geographic impact of Changyu Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changyu Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changyu Pan more than expected).

Fields of papers citing papers by Changyu Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changyu Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changyu Pan. The network helps show where Changyu Pan may publish in the future.

Co-authorship network of co-authors of Changyu Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Changyu Pan. A scholar is included among the top collaborators of Changyu Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changyu Pan. Changyu Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lv, Fang, Xiaoling Cai, Dayi Hu, et al.. (2019). Characteristics of Newly Diagnosed Type 2 Diabetes in Chinese Older Adults: A National Prospective Cohort Study. Journal of Diabetes Research. 2019. 1–9. 10 indexed citations
3.
Pan, Changyu, Jorge Luiz Gross, Wenying Yang, et al.. (2016). A Multinational, Randomized, Open-label, Treat-to-Target Trial Comparing Insulin Degludec and Insulin Glargine in Insulin-Naïve Patients with Type 2 Diabetes Mellitus. Drugs in R&D. 16(2). 239–249. 33 indexed citations
4.
5.
Ji, Linong, Puhong Zhang, Jianping Weng, et al.. (2015). Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China—Study Design and Baseline Characteristics. Diabetes Technology & Therapeutics. 17(10). 735–744. 33 indexed citations
6.
Garg, Satish K., Nick Freemantle, Masato Odawara, et al.. (2014). Patient-Led Versus Physician-Led Titration of Insulin Glargine in Patients with Uncontrolled Type 2 Diabetes: A Randomized Multinational Atlas Study. Endocrine Practice. 21(2). 143–157. 37 indexed citations
7.
Lu, Yanhui, Juming Lu, Chunlin Li, et al.. (2012). Cognitive function with glucose tolerance status and obesity in Chinese middle-aged and aged adults. Aging & Mental Health. 16(7). 911–914. 12 indexed citations
8.
Wang, Xianling, et al.. (2012). Chronic inflammatory demyelinating polyneuropathy mimicking diabetic neuropathy in a young female with type 2 diabetes mellitus. Diabetes Research and Clinical Practice. 96(2). e15–e17. 4 indexed citations
9.
Liu, Min, Changyu Pan, & Mengmeng Jin. (2011). A Chinese Diabetes Risk Score for Screening of Undiagnosed Diabetes and Abnormal Glucose Tolerance. Diabetes Technology & Therapeutics. 13(5). 501–507. 42 indexed citations
10.
Gong, Yuping, Baoan Wang, Lijuan Yang, et al.. (2009). Clinical and epigenetic study of a case with adrenal hypoplasia congenita caused by a novel DAX-1 gene mutation. Zhonghua neifenmi daixie zazhi. 25(1). 62–63. 1 indexed citations
11.
12.
Lu, Yanhui, Juming Lu, Shuyu Wang, et al.. (2008). [Two-year follow-up for patients with pre-diabetes that reverted to normal glucose in the first year].. PubMed. 88(20). 1394–7. 1 indexed citations
13.
Pan, Changyu, Wenying Yang, Jacqueline Barona, et al.. (2008). Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. Diabetic Medicine. 25(4). 435–441. 144 indexed citations
14.
Gu, Weijun, Juming Lu, Guoqing Yang, et al.. (2008). Plasma homocysteine thiolactone associated with risk of macrovasculopathy in Chinese patients with type 2 diabetes mellitus. Advances in Therapy. 25(9). 914–924. 26 indexed citations
15.
Pan, Changyu, et al.. (2007). Post-Marketing Surveillance of Acarbose Treatment in Patients with Type 2 Diabetes Mellitus and Subjects with Impaired Glucose Tolerance in China. Clinical Drug Investigation. 27(6). 397–405. 20 indexed citations
16.
Pan, Changyu, et al.. (2006). [Cross-sectional study on the prevalence of metabolic syndrome in patients with coronary heart disease in China].. PubMed. 86(30). 2095–8. 4 indexed citations
17.
Lu, Yanhui, Juming Lu, Shuyu Wang, et al.. (2006). [Comparison of the diagnostic criteria of metabolic syndrome by International Diabetes Federation and that by Chinese Medical Association Diabetes Branch].. PubMed. 86(6). 386–9. 44 indexed citations
18.
Pan, Changyu, et al.. (2006). Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. Diabetes Research and Clinical Practice. 76(1). 111–118. 72 indexed citations
19.
Pan, Changyu, Yan Gao, Xīn Gào, et al.. (2002). [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].. PubMed. 41(6). 388–92. 2 indexed citations
20.
Kaplan, Michael M., Changyu Pan, Philip Gordon, Jenn‐Kuen Lee, & Barbara A. Gilchrest. (1988). Human Epidermal Keratinocytes in Culture Convert Thyroxine to 3,5,3′-Triiodothyronine by Type II Iodothyronine Deiodination: A Novel Endocrine Function of the Skin*. The Journal of Clinical Endocrinology & Metabolism. 66(4). 815–822. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nanwei Tong Breakdown of academic impact, for papers by Naohiko Furuyoshi Breakdown of academic impact, for papers by Mary Lou Perry Breakdown of academic impact, for papers by S. Motoyoshi Breakdown of academic impact, for papers by Sam Dagogo‐Jack Breakdown of academic impact, for papers by Giuseppe Seghieri Breakdown of academic impact, for papers by Tae Jung Oh Breakdown of academic impact, for papers by György Jermendy Breakdown of academic impact, for papers by Adriaan Kooy Breakdown of academic impact, for papers by Chul Sik Kim
Rankless by CCL
2026